Cargando…
A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models
Proteasome inhibitors are the cornerstone of multiple myeloma treatment, but challenges still remain despite the increased survival rates. We conducted a review on the role of curcumin, a natural product, as an adjunct to bortezomib and carfilzomib in preclinical multiple myeloma models. Four studie...
Autores principales: | Pandya, Shaunak K., Pandya, Arati, Larsen, Ashley, Gowin, Krisstina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996714/ https://www.ncbi.nlm.nih.gov/pubmed/36879488 http://dx.doi.org/10.1177/15347354231159322 |
Ejemplares similares
-
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models
por: Park, Jonghoon, et al.
Publicado: (2016) -
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012) -
Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma
por: Pandya, Shaunak K, et al.
Publicado: (2021) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020) -
Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
por: Win, Hninyee, et al.
Publicado: (2020)